Anti-cancerous medications and PTEN treatment modalities for the control of endometrial malignancy

Komal Pal; Gaurav Verma; Ajay Kumar

doi:10.53730/ijhs.v6nS1.8697

Authors

Komal Pal Department of Biotechnology, Faculty of Engineering & Technology, Rama University, Kanpur-209217, India
Gaurav Verma Department of Biotechnology, Naraina Vidyapeeth Engineering & Management Institute, Gangaganj Panki, Kanpur-208020, India
Ajay Kumar
palkomal.rk02@gmail.com
Department of Biotechnology, Faculty of Engineering & Technology, Rama University, Kanpur-209217, India

Keywords:

Drugs, Endometrial, Radiotherapy, Carcinogenic Pills, Tumors

Abstract

Endometrial most tumors still up in the air to emerge at Post menopause but at this point its miles been apparent pre-menopause. Unsettling influence in estrogen and progesterone degrees alters the monthly cycle in a regenerative framework. Growing out of and the crazy blast of uterus linage reasons the development of thick covering onto the parts of the uterus which reasons unbalanced draining and distinctive hormonal aggravation incurring most malignancies and diverse digestion unsettling influences. In connection with most diseases, a Lynch disorder, moreover known as Hereditary Non-Polyposis Colorectal Cancer (HNPCC) expands the danger to survivability. Utilization of immunosuppressive specialists, Anti-dangerous Drugs, and inhibitors are stifling utilizing chemotherapy, imaging systems, and radiotherapy which comparatively reasons harm to the cells gift with inside the spot of the attacked cells. Endometrial most malignancies can't be relieved anyway intrusion might be suppressed with the utilization of against carcinogenic pills that have demonstrated unreasonable limit and adequacy with the sickness.

Downloads

Download data is not yet available.

References

M. Mihm, S. Gangooly, and S. Muttukrishna, “The normal menstrual cycle in women,” Anim. Reprod. Sci., vol. 124, no. 3–4, pp. 229–236, 2011

M. Wilczyński, J. Danielska, and J. Wilczyński, “An update of the classical Bokhman’s dualistic model of endometrial cancer,” Prz. Menopauzalny, vol. 15, no. 2, pp. 63–68, 2016

S. F. Lax, B. Kendall, H. Tashiro, R. J. C. Slebos, and L. H. Ellenson, "The frequency of p53, K-ras mutations, and microsatellite instability differ in uterine endometrioid and serous carcinoma: Evidence of distinct molecular genetic pathways," Cancer, vol. 88, no. 4, pp. 814–824, 2000.

Wang JY, Wang WP. B7-H4, a promising target for immunotherapy. Cell Immunol. 2020;347:104008.

F. S. Liu, “Molecular carcinogenesis of endometrial cancer,” Taiwan. J. Obstet. Gynecol., vol. 46, no. 1, pp. 26–32, 2007

B. T. Hennessy, D. L. Smith, P. T. Ram, Y. Lu, and G. B. Mills, “Exploiting the PI3K/AKT pathway for cancer drug discovery,” Nat. Rev. Drug Discov., vol. 4, no. 12, pp. 988–1004, 2005

Rodriguez-Garcia A, Sharma P, Poussin M, et al. CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies. Mol Ther. 2020;28(2):548–60.

J. A. Engelman, J. Luo, and L. C. Cantley, “The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism,” Nat. Rev. Genet., vol. 7, no. 8, pp. 606–619, 2006

S. Mabuchi, H. Kuroda, R. Takahashi, and T. Sasano, “The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer,” Gynecol. Oncol., vol. 137, no. 1, pp. 173–179, 2015

Cui, L., Yang, G., Ye, J., Yao, Y., Zhou, J., 2020. Dioscin elicits anti-tumour immunity by inhibiting macrophage M2 polarization via JNK and STAT3 pathways in lung cancer. J. Cell Mol. Med. 24, 9217–9230.

H. Sun et al., “Mutational Analysis of the PTEN Gene in Endometrial Carcinoma and Hyperplasia,” Am. J. Clin. Pathol., vol. 115, no. 1, pp. 32–38, 2001

M. R. Quddus, B. A. Ologun, C. J. Sung, M. M. Steinhoff, and W. D. Lawrence, “Utility of PTEN expression of endometrial ‘surface epithelial changes’ and underlying atypical endometrial hyperplasia,” Int. J. Gynecol. Pathol., vol. 28, no. 5, pp. 471–476, 2009

D. Kong et al., “Pten1 is frequently mutated in primary endometrial carcinomas,” Nat. Genet., vol. 17, no. 2, p. 144, 1997

Jiang, W., Lin, M., Wang, Z., 2020. Dioscin: a new potential inhibitor of Skp2 for cancer therapy. EBioMedicine 51, 102593.

G. L. Mutter, “PTEN, a protean tumor suppressor,” Am. J. Pathol., vol. 158, no. 6, pp. 1895–1898, 2001

Liu, M.-M., Ma, R.-H., Ni, Z.-J., Thakur, K., Cespedes-Acu˜ na, C.L., Jiang, L., Wei, Z.-J., 2020. Apigenin 7-O-glucoside promotes cell apoptosis through the PTEN/PI3K/AKT pathway and inhibits cell migration in cervical cancer HeLa cells. Food Chem. Toxicol. 146, 111843.

I. Alvarado-Cabrero, “Molecular Oncology of Gynecologic Tumors,” Arch. Med. Res., vol. 51, no. 8, pp. 817–826, 2020

A. Pavlidou and N. F. Vlahos, “Molecular alterations of PI3K/Akt/mTOR pathway: A therapeutic target in endometrial cancer,” Sci. World J., vol. 2014, 2014

J. Yang, J. Nie, X. Ma, Y. Wei, Y. Peng, and X. Wei, “Targeting PI3K in cancer: Mechanisms and advances in clinical trials,” Mol. Cancer, vol. 18, no. 1, pp. 1–28, 2019,

Sun, Y.-S., Thakur, K., Hu, F., Cespedes-Acu˜ na, C.L., Zhang, J.-G., Wei, Z.-J., 2020a. Icariside II suppresses cervical cancer cell migration through JNK modulated matrix metalloproteinase-2/9 inhibition in vitro and in vivo. Biomed. Pharmacother. 125, 110013.

Sun, Y.-S., Thakur, K., Hu, F., Zhang, J.-G., Wei, Z.-J., 2020b. Icariside II inhibits tumorigenesis via inhibiting AKT/Cyclin E/CDK 2 pathway and activating mitochondria-dependent pathway. Pharmacol. Res. 152, 104616.

Y. Y. Wu et al., "The dual PI3K/mTOR inhibitor BEZ235 restrict the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens," J. Exp. Clin. Cancer Res., vol. 38, no. 1, pp. 1–16, 2019

J. J. Wallin et al., “GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway,” Mol. Cancer Ther., vol. 10, no. 12, pp. 2426–2436, 2011

Guo, Z., Xing, Y., Wang, W., Lai, J., 2020. Apigetrin inhibits thyroid cancer cell growth and proliferation through down-regualtion of HIF1 alpha and VEGF expression. Indian J Pham Educ 54, 668–673.

S. M. Maira et al., “Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity,” Mol. Cancer Ther., vol. 7, no. 7, pp. 1851–1863, 2008

X. Fang, X. Zhou, and X. Wang, “Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma,” Biomark. Res., vol. 1, no. 1, 2013

S. Blagden et al., “First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer,” Clin. Cancer Res., vol. 20, no. 23, pp. 5908–5917, 2014

B. M. Slomovitz and R. L. Coleman, “The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer,” Clin. Cancer Res., vol. 18, no. 21, pp. 5856–5864, 2012,

Chen, C., Wang, Y., Chen, S., Ruan, X., Liao, H., Zhang, Y., Sun, J., Gao, J., Deng, G., 2020. Genistein inhibits migration and invasion of cervical cancer HeLa cells by regulating FAK-paxillin and MAPK signaling pathways. Taiwan. J. Obstet. Gynecol. 59, 403–408.

J. J. Harding et al., “Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor,” Invest. New Drugs, vol. 37, no. 2, pp. 271–281, 2019,

M. L. Sos et al., “Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer,” Proc. Natl. Acad. Sci. U. S. A., vol. 106, no. 43, pp. 18351–18356, 2009

J. C. Bendell et al., “Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors,” J. Clin. Oncol., vol. 30, no. 3, pp. 282–290, 2012

Hussain, S.S., Zhang, F., Zhang, Y.-Y., Thakur, K., Naudhani, M., Cespedes-Acu˜ na, C.L., Wei, Z.-J., 2020. Stevenleaf from Gynostemma Pentaphyllum inhibits human hepatoma cell (HepG2) through cell cycle arrest and apoptotic induction. Food Sci Hum Well 9, 295–303.

S. Jia et al., “Essential roles of PI(3)K-p110β in cell growth, metabolism and tumorigenesis,” Nature, vol. 454, no. 7205, pp. 776–779, 2008

C. Fritsch et al., “Characterization of the novel and specific PI3Ka inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials,” Mol. Cancer Ther., vol. 13, no. 5, pp. 1117–1129, 2014

I. A. Mayer et al., “A Phase Ib Study of Alpelisib (BYL719), a PI3Ka-Specific Inhibitor, with Letrozole in ERþ/HER2 Metastatic Breast Cancer,” Clin. Cancer Res., vol. 23, no. 1, pp. 26–34, 2017

M. Elkabets et al., "MTORC1 inhibition are required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer," Sci. Transl. Med., vol. 5, no. 196, 2013

S. Jain et al., “Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy,” Breast Cancer Res. Treat., vol. 171, no. 2, pp. 371–381, 2018

Kikuchi, H., Yuan, B., Hu, X., Okazaki, M., 2019. Chemopreventive and anticancer activity of flavonoids and its possibility for clinical use by combining with conventional chemotherapeutic agents. Am J Cancer Res 9, 1517–1535.

R. M. J. M. Van Geel et al., “A phase Ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer,” Cancer Discov., vol. 7, no. 6, pp. 610–619, 2017

S. E. M. Herman et al., “Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals,” Blood, vol. 116, no. 12, pp. 2078–2088, 2010

J. Baselga et al., "Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomized, double-blind, placebo-controlled, phase 3 trial," Lancet Oncol., vol. 18, no. 7, pp. 904–916, 2017

A. K. Gopal et al., “PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma,” N. Engl. J. Med., vol. 370, no. 11, pp. 1008–1018, 2014

I. W. Flinn et al., “Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma,” Blood, vol. 123, no. 22, pp. 3406–3413, 2014

B. S. Kahl et al., “A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL),” Blood, vol. 123, no. 22, pp. 3398–3405, 2014

J. R. Brown et al., “Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia,” Blood, vol. 123, no. 22, pp. 3390–3397, 2014,

Li, Y., Feng, X., Yu, X., Wang, Y., Liu, Y., Ye, X., Jia, R., Chen, W., Yu, T., Zheng, X., 2020. Radix Tetrastigma flavonoids inhibit the migration and promote the apoptosis of A549 cells both in vitro and in vivo. J Funct Foods 72, 104076.

B. L. Lampson et al., "Idelalisib has given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity," Blood, vol. 128, no. 2, pp. 195–203, 2016

S. M. Smith et al., "Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trial," Lancet Haematol., vol. 4, no. 4, pp. e176–e182, 2017

A. Mayssara A. Abo Hassanin Supervised, “済無No Title No Title No Title,” Pap. Knowl. . Towar. a Media Hist. Doc., vol. 1, no. 206, 2014.

S. M. O’Brien et al., “A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia,” Blood, vol. 126, no. 25, pp. 2686–2694, 2015

R. R. Furman et al., “Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia,” N. Engl. J. Med., vol. 370, no. 11, pp. 997–1007, 2014

J. A. Jones et al., "Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia: an open-label, randomized phase 3 trial," Lancet Haematol., vol. 4, no. 3, pp. e114–e126, 2017

M. R. Wilson et al., “ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion,” Nat. Commun., vol. 10, no. 1, 2019, DOI: 10.1038/s41467-019-11403-6.

Lin, J., Tian, J., Shu, C., Cheng, Z., Liu, Y., Wang, W., Liu, R., Li, B., Wang, Y., 2020. Malvidin-3-galactoside from blueberry suppresses the growth and metastasis potential of hepatocellular carcinoma cell Huh-7 by regulating apoptosis and metastases pathways. Food Sci Hum Well 9, 136–145.

T. Vu and F. X. Claret, “Trastuzumab: Updated mechanisms of action and resistance in breast cancer,” Front. Oncol., vol. 2 JUN, no. June, pp. 1–7, 2012, DOI: 10.3389/fonc.2012.00062.

J. Albanell, J. Colony, A. Rovira, B. Mellado, and P. Gascón, "Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4," Adv. Exp. Med. Biol., vol. 532, pp. 253–268, 2003, DOI: 10.1007/978-1-4615-0081-0_21.

I. Meijerman, J. H. Beijnen, and J. H. M. Schellens, “C linical P harmacology,” Clin. Pharmacol. L-Arginine, no. 2, pp. 742–752, 2006, doi: 10.1634/theoncologist.2010-0035.

Genentech, “Herceptin® (trastuzumab) [package insert],” pp. 1–38, 2018, [Online]. Available: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103792s5337lbl.pdf.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2022). Post-pandemic health and its sustainability: Educational situation. International Journal of Health Sciences, 6(1), i-v. https://doi.org/10.53730/ijhs.v6n1.5949

L. M. Rogers, S. Veeramani, and G. J. Weiner, “Complement in monoclonal antibody therapy of cancer,” Immunol. Res., vol. 59, no. 1–3, pp. 203–210, 2014, DOI: 10.1007/s12026-014-8542-z.

S. Mamidi, M. Cinci, M. Hausmann, V. Fehring, and M. Kirschfink, "Lipoplex mediated silencing of memregulators (CD46, CD55, and CD59) enhances the complement-dependent anti-tumor activity of trastuzumab and pebrane rtuzumab," Mol. Oncol., vol. 7, no. 3, pp. 580–594, 2013, doi: 10.1016/j.molonc.2013.02.011.